Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon
I Can Extract Side Effects
Chapter 296

Scouring Abandoned Drug Formulas

2,688 words 9 min read 0 views 3mo ago Source ​
Skip to the end of the chapter
Prev
Next

Unsurprisingly, Wei Kang received another call from Andre.

"Dear Wei, it's like this: last time I ordered a batch of ARC1 protein samples, they received unanimous approval from the Pfizer scientist team. Everyone is very optimistic about this technology and wants to apply it to more areas of biopharmaceuticals."

"So, on behalf of the company, I'd like to talk to you about patent licensing fees."

Andre didn't hide anything and directly stated his purpose. He had already figured out Wei Kang's general temperament and knew that the other party was also quite straightforward. Only by treating him with sincerity could they continue to cooperate.

"No problem, our cooperation has always been very pleasant. I'll give you a discount for an old friend," Wei Kang replied with a smile.

Speaking of discounted prices, Andre suddenly had a flash of inspiration and remembered something.

Mr. Wei seems to have a rather unique hobby: he likes to collect discarded prescriptions. In the last round of negotiations on Anti-cancer Drug, he even required pharmaceutical companies to provide discarded prescriptions in order to be eligible to bid.

In this light, we might as well cater to their preferences and see if we can negotiate the price down a bit more.

Andre said with some difficulty, "Dear Wei, the company has recently made a series of strategic adjustments to focus on the research and development of innovative drugs and vaccines. We have been making large-scale acquisitions in the past six months, which has greatly depleted our cash flow."

"Especially since we spent $11.6 billion last month to acquire the pharmaceutical company Biohaven, we are now short of funds and don't have much money left. However, Pfizer is a large and powerful company with many subsidiaries and pipelines. If you are interested, we can exchange some of our divested businesses."

"In short, we hope to minimize cash payments and preferably pay patent licensing fees in other ways."

"Oh," Wei Kang suddenly became interested and asked, "What strategic adjustments are you making? Which businesses are you going to divest or sell?"

Andre immediately launched into a long speech. "One of the company's goals now is to embrace digitalization. We recently announced a digital upgrade plan to shift more medical staff to online interaction, expand internet channels, and strengthen the digital development strategy. Three Purities has always done a great job in this regard, and we should learn from you."

"We will also focus on multiple areas such as oncology, Rare Disease, immunity and inflammation, and vaccines, and have acquired four companies in these areas, gaining access to multiple pipelines in development, including Lyme disease vaccines, blockbuster migraine drugs, respiratory antiviral drugs, and immune inflammatory diseases."

"Therefore, we will definitely sell some of our business to recoup funds and maintain a balance between income and expenditure."

"The businesses that have already been spun off, including the consumer healthcare business and the generic drug business, have each been established into joint ventures. We only hold shares in them. This year, we will completely sell all our shares and exit these two businesses. If Three Purities is also interested, everything is negotiable."

Andre continued calmly, "In addition, all the acquired companies will divest and sell off their bad assets, including failed R&D projects, abandoned prescriptions, expired patents, discontinued drugs, loss-making businesses, and so on."

"As far as I know, in addition to Pfizer, other multinational pharmaceutical companies are also adjusting their strategic layout and divesting non-performing assets to alleviate performance pressure."

"Sanofi has been hit hard recently and is preparing to sell its stake in its active pharmaceutical ingredient company. Merck is also selling its women's health business, and GSK plans to divest its consumer healthcare business. AstraZeneca has also sold several blockbuster drugs in various fields."

Andre has worked in the pharmaceutical industry for many years and is very familiar with the movements of major pharmaceutical companies, constantly revealing the latest developments.

Wei Kang listened intently, quite tempted. Three Purities now has an annual revenue of 40 billion yuan, which means it has a lot of money at its disposal. It can completely acquire new growth points through mergers and acquisitions, just like other pharmaceutical companies.

In recent years, competition among pharmaceutical companies has become increasingly fierce. Faced with pressure from drug price reductions, centralized procurement, and patent expiration, many multinational pharmaceutical companies are selling off their assets to weather the storm and find new business opportunities.

Although Three Purities has many blockbuster and flagship drugs, it still lacks in the layout of the entire drug production line. This is a disadvantage due to its short history of development, and it cannot compare with the rich accumulation of pharmaceutical companies that have been around for hundreds of years.

Giants like Pfizer have hundreds of drugs in development every year, and dozens of them fail or are scrapped. Over the years, the number of formulas gathering dust in their warehouses is probably in the tens of thousands.

Wei Kang felt a surge of excitement just thinking about it, but unfortunately, none of these prescriptions belonged to him, so he couldn't make use of them and they could only stay at the bottom of the ballast. He couldn't help but sigh with regret.

Just then, the words 'failed R&D project,' 'discarded prescription,' and 'spin-off' suddenly drifted into my ears.

He was stunned for a moment, then his eyes lit up and his heart began to pound.

That's great! How come he didn't think of that?

If you don't have enough discarded prescriptions, you can just buy them from someone else.

When pharmaceutical companies are doing well, they may be reluctant to sell off assets. However, when they are restructuring their businesses and selling off non-performing assets, they are naturally willing to sell at a low price to obtain some cash.

Of course, it shouldn't be too obvious; it can be acquired in a package with other cheap assets.

These multinational pharmaceutical companies are all pure capitalists, absolutely willing to sell and squeeze every last drop of profit out of each other.

After all, Wei Kang needs is a prescription that was discarded from Phase I clinical trials.

Which slightly larger pharmaceutical company doesn't have dozens of discarded prescriptions piled up in its warehouse?

If they sell them all, they could make a few million US dollars. For many pharmaceutical companies, this would be a windfall, and any amount they could recover from their losses would be a bonus.

For some pharmaceutical companies that are on the verge of bankruptcy, this money is a lifeline, allowing them to survive for a little longer and perhaps even be brought back to life.

Wei Kang was deeply moved, but his face remained impassive as he nodded in agreement, saying, "Indeed, after these adjustments, Pfizer will surely be able to revitalize itself and reach new heights in the field of innovative drugs."

"I am very interested in what you have said. As you know, Three Purities's foundation is still very weak and it needs to acquire more other businesses. Pfizer's target areas do not overlap with Three Purities's, so there is a lot of room for cooperation between the two sides."

Among the key areas Pfizer is focusing on, oncology is definitely a collaboration with Three Purities's Anti-cancer Drug.

Rare Disease are a huge category, with as many as three thousand diseases, which is more than enough to cover them all, so they cannot pose a threat.

As for the vaccine business, including antiviral and immune-inflammatory vaccines, Three Purities has not entered these markets at all, and there is no competition involved.

Seeing that Wei Kang's response had become much more enthusiastic, Andre burst into laughter.

In his good mood, he also spoke his mind.

"My dear Wei, you're always so smart. The pharmaceutical market is huge, and even a small part of it can be very profitable. We can complement each other in many ways and share this pie together."

"Actually, I don't agree with the actions of the Broad Institute. Being too greedy will only kill the goose that lays the golden eggs and ruin the future of gene patents. I am more optimistic about cooperating with Three Purities. You have stronger technology, but you are more inclusive and have a longer-term vision."

"With the ARC1 protein patent, Three Purities is already invincible in the field of Gene Editing. What you need are friends, the more the better, so that you can obtain a continuous stream of profits. What do you say?"

Wei Kang was very impressed. Andre was much smarter than he had imagined, and it was clear that his stance belonged to the liberal faction, not the conservative faction.

"This person is someone I could try to win over and use for my own purposes. I just don't know how many people like him there are in the West," he thought to himself.

The two sides had a very pleasant conversation and quickly reached a preliminary agreement.

In a few days, Andre will come with a team to formally sign the patent licensing agreement.

Meanwhile, Wei Kang is also very interested in the non-performing assets that Pfizer is about to sell.

The assets being divested and sold this time are all non-performing assets of the acquired companies, so there's no heartache in selling them.

Pfizer only values the blockbuster drugs of those companies and their research and development capabilities in that field; it doesn't care about anything else.

Wei Kang quickly negotiated a very cheap price.

Pfizer truly lives up to its reputation as a major player in mergers and acquisitions, spending billions of dollars annually in the pharmaceutical industry. This super-big spender has a huge inventory of acquisitions, having acquired no fewer than 10 companies in just the last two years.

This time, they sold off the non-performing assets of eight acquired companies in one go, including but not limited to all abandoned prescriptions, delisted drugs, drugs with no development prospects, and several patents that were not selling well and were about to expire.

In order to secure a discount on patent licensing fees, Andre even persuaded the CEO to include some of Pfizer's obsolete drug formulas in the patent.

Of course, these are all relatively old stock items, having been gathering dust on laboratory shelves for at least five or six years, the kind that I wouldn't mind giving away for free.

Because it's a clearance sale, the price is very affordable, around 20 million US dollars.

Pfizer does not intend to pay in cash; instead, it will include all payments in the first batch of patent licensing fees.

Wei Kang essentially reduced some Patent Fee, but in return, it received a large number of obsolete prescriptions and unpromising drugs.

Pfizer sacrificed some of its underperforming assets in exchange for a significant discount and a reduction in patent licensing fees.

It was all done through bartering; not a single penny of cash was spent.

Both sides were overjoyed and felt they had gotten a great deal.

Having tasted success through this incident, Wei Kang began to set its sights on other multinational pharmaceutical companies.

Just as Andre said, Sanofi, AstraZeneca, Merck, Novartis, and other pharmaceutical companies are all downsizing and restructuring, shedding non-performing assets. He could easily do the same and use patent licensing fees to acquire obsolete drug formulas.

The news of Pfizer's deal with Three Purities quickly spread throughout the industry.

******

The capital of the Sakura Country, Dajing.

In a high-rise building in the city center, Weicai Pharmaceutical CEO Okada Murao sighed and worried about the company's plummeting performance.

Eisai Pharmaceutical is one of Sakura Country's five major pharmaceutical giants, with annual sales reaching $6 billion, ranking among the top 50 pharmaceutical giants in the world.

This is a typical pharmaceutical company that relied on blockbuster products to quickly build its business. It once ranked among the top 20 in the world, but times have changed and Eisai's position in the global pharmaceutical market is no longer what it used to be.

With its two blockbuster products, Donepezil and Rabeprazole, the company has partnered with Pfizer and Johnson & Johnson & Johnson respectively. Thanks to the efforts of these two giants, the company has generated billions of dollars in revenue in just a few years.

However, innovative drugs are always a high-risk gamble, and to achieve long-term success in the innovative drug industry, the patent cliff problem must be solved.

The patent cliff refers to the situation where, after a patent expires, a large number of inexpensive generic drugs emerge and seize the market, causing the sales of the original drug to plummet as if falling off a cliff.

Eisai has successfully created two blockbuster products, but this does not mean that its R&D capabilities are on par with multinational giants.

Conversely, Eisai, which successfully went global with its Me-too improved drugs, has a significant gap in innovation capabilities compared to Western pharmaceutical giants.

When the company was at its peak, it failed to plan ahead and carry out a large number of mergers and acquisitions in a timely manner to alleviate the crisis in its R&D pipeline, resulting in a failed transformation and facing a huge crisis.

Especially in the last decade, Eisai has invested huge sums in research and development, but with little return. Due to a lack of innovation and the inability to resolve the patent cliff issue, the company is currently in trouble.

However, its biggest best-selling product Donepezil, is an AD drug, whose main function is to improve the cognitive abilities of Alzheimer's disease's patients.

This undoubtedly clashes head-on with Three Purities's AD Special Effect Drug.

Almost overnight, Eisai's flagship drug became unwanted, and sales plummeted.

This is no longer a patent cliff issue; it's a complete dead end.

This medicine is completely useless now.

This undoubtedly dealt Eisai the final blow, and the company began its decline from then on.

As CEO, Okada Murao has been racking his brains for the past two years, barely managing to survive by relying on the domestic market.

Although a lean camel is still bigger than a horse, the company's revenue has dropped from $6 billion to $2 billion.

Bad news keeps coming in: several new drug projects have been abandoned. A lot of money has been spent, but no profit is in sight, and the business is already losing money.

If no new revenue streams are found, the company will eventually become just another generic drug manufacturer, leading to losses and bankruptcy.

His face was sallow, his expression haggard, and he looked at the work report in front of him with a worried expression.

As he watched, veins bulged on his forehead, his eyes turned red, and his gaze was filled with anger. He gritted his teeth and said...

"Damn the Three Purities, it's their news again!"

"Damn it, the news is that they've reached cooperation agreements with major pharmaceutical companies. This is unbelievable."

"It's all the fault of the China. They stole the market share from Eisai's Alzheimer's disease's drugs, leaving us in this predicament."

Okada Murao was seething with hatred, but he was helpless and could only rage in a fit of impotence, slamming his fist on the table.

"I hate it so much! Why wasn't it Eisai who developed these drugs? Anti-cancer Drug, AD Special Effect Drug, they should all belong to the Yamato people."

He cursed the Sanqing Group fiercely as he flipped through the work reports.

Suddenly, he stopped, his eyes wide open, staring intently at the paper in front of him.

After a long while, he suddenly began to breathe heavily, his expression extremely excited, as if he had discovered something incredible.

"Fuck, I can't believe I only realized today that Wei Kang is actually good at improving abandoned medicine prescriptions."

"Sanqing Group has been scavenging all kinds of discarded medicinal formulas. They must have ulterior motives and other uses. It's impossible that they would buy them and find them completely useless."

"Could it be that their drugs were all improved versions of discarded drugs, which were then revitalized and achieved success?"

"In other words, many prescriptions have actually been successfully developed, but no one has discovered those new treatment directions yet."

"Damn it, how come I didn't think of that?"

"Perhaps we could try looking for new treatment options from discarded prescriptions?"

"This is undoubtedly much easier and more convenient than developing innovative drugs from scratch."

"Is this the secret to the success of the Sanqing Group?"

"It's mine now!"

End of Chapter
Prev
NovelSummaries
Next

Explore the wiki

Wei Kang
Three Purities
China

Comments

No comments yet.
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS